Research Article
The Impact of Hyperoxia on Outcome of Patients Treated with Noninvasive Respiratory Support
Table 3
Patient profiles treated only noninvasively.
| | | Hyperoxia group n = 46 | Normoxia group n = 85 | value |
| | Age (years) | 69.1 ± 17.3 | 68.3 ± 14.9 | >0.05 | | APACHE II | 15.0 ± 6.6 | 15.0 ± 6.1 | >0.05 | | Highest PaO2 (mmHg) | 134.2 ± 61.5 | 100.6 ± 44.6 | <0.001 | | ICU stay (days) | 7.2 ± 5.4 | 6.2 ± 4.3 | >0.05 | | Hospital stay (days) | 30.9 ± 38.4 | 23.2 ± 20.6 | >0.05 | | Gender (f/m) | 23/23 | 46/39 | >0.05 | | Comorbidities (n, %) | | | | | COPD | 7 (15.2) | 33 (38.8) | <0.01 | | CHD | 10 (21.7) | 15 (17.6) | >0.05 | | CHF | 11 (23.9) | 19 (22.4) | >0.05 | | CRF | 9 (19.6) | 12 (14.1) | >0.05 | | HT | 25 (54.3) | 51 (60.0) | >0.05 | | DM | 13 (28.3) | 29 (34.1) | >0.05 | | CLF | 7 (15.2) | 4 (4.7) | >0.05 | | Malignancy | 15 (32.6) | 21 (24.7) | >0.05 | | Dementia | 3 (6.5) | 3 (3.5) | >0.05 | | ICU mortality (n, %) | 7 (15.2) | 8 (9.4) | >0.05 | | Hospital mortality (n, %) | 19 (41.3) | 13 (15.3) | <0.001 | | O2 treatment modality (n, %) | | | | | Supplemental oxygen/NIMV | 25/21 | 27/58 | <0.02 |
|
|
COPD: chronic obstructive pulmonary disease, CHD: coronary heart disease, CHF: congestive heart failure, CRF: chronic renal failure, HT: hypertension, DM: diabetes mellitus, and CLF: chronic liver failure.
|
